Key Highlights
- Haleon PLC (LSE:HLN) fell 0.91% on 29 September 2026 after a cautious note from JPMorgan.
- JPMorgan placed its underweight-rated Haleon on negative catalyst watch ahead of third-quarter results on 29 October.
- The bank said third-quarter like-for-like sales growth is tracking at about 3%, the bottom of Haleon's 3% to 5% guidance range.
- JPMorgan cut its 2027 adjusted EPS forecast by 3% to 22p and its 2028 estimate by 5% to 23.09p.
- It expects Haleon to reset its medium-term sales growth target in February 2027.
Haleon Slips on Broker Warning
Haleon PLC (LSE:HLN) closed 0.91% lower on Tuesday after JPMorgan issued a cautious note on the consumer health group behind brands such as Sensodyne, Panadol, Advil, Voltaren and Centrum. The decline came on a day when the FTSE 100 fell 0.45% to 10,636.71 and defensive stocks broadly lost ground as bond yields surged.
JPMorgan, which rates Haleon underweight, placed the stock on negative catalyst watch ahead of its third-quarter results, scheduled for 29 October. A negative catalyst watch indicates that the bank expects the upcoming results to be a disappointment that could weigh on the share price.
What JPMorgan Said
The bank said Haleon's third-quarter like-for-like sales growth is tracking at about 3%, which would leave the company at the bottom of its 3% to 5% guidance range for a second consecutive year. Analysts said this performance makes the medium-term target of 4% to 6% like-for-like growth increasingly difficult to sustain.
JPMorgan cut its third-quarter Organic Sales growth forecast to 3% from 3.3%, mainly because of a weaker European outlook, which it now sees at minus 0.5%. It also noted that lower year-on-year US flu incidence removes a potential near-term tailwind for cold and flu products.
Looking further ahead, the bank lowered its 2027 like-for-like growth forecast to 3.3% from 4.1% and its EBIT Margin forecast to 24.1% from 24.5%, expecting Haleon to increase Investment to support sales growth. It cut its 2027 adjusted EPS forecast by 3% to 22p and its 2028 estimate by 5% to 23.09p. JPMorgan's 2028 EPS estimate is now about 7% below consensus.
Structural Concerns
JPMorgan highlighted deeper issues in Haleon's portfolio. It said over-the-counter medicines and vitamins, minerals and supplements, which together account for about 70% of sales, operate in structurally slower-growing markets and have been losing global market share. Volume growth has averaged only about 1% a year since 2022, according to the bank.
The analysts also questioned the sustainability of recent margin gains. Haleon's roughly 200 basis point margin expansion over 2024 to 2026 has been driven largely by cost savings rather than operating leverage, leaving less room for further improvement without higher reinvestment.
On mergers and acquisitions, JPMorgan said potential deals could improve Haleon's portfolio mix but might also divert management attention from the core Business and weigh on returns on invested capital.
Why Haleon Stock Is in Focus
Haleon, spun off from GSK in 2022, is one of the world's largest consumer health companies and a key defensive holding for many investors. Its strength in oral health, led by Sensodyne, has been a consistent growth driver, while other categories have been more volatile.
The company's ability to meet its medium-term growth targets is central to its valuation. With consensus expecting like-for-like growth of about 4.3% to 4.4% in 2027 and 2028, well above JPMorgan's forecasts, the gap between market expectations and the bank's view creates risk around upcoming results.
Key Reasons Behind the 0.91% Decline
The first reason is the JPMorgan negative catalyst watch and forecast cuts, which raised concerns about the upcoming third-quarter results.
The second reason is sector weakness. Defensive consumer stocks, including Unilever and British American Tobacco, also fell as rising bond yields reduced the appeal of steady Dividend payers.
The third reason is the broader macro backdrop, with the US 30-year Treasury Yield at its highest since 2002 and UK gilt yields near 5.43%, pressuring Equity valuations.
What Investors Should Watch Next
Haleon's third-quarter results on 29 October are now the key event. Investors will focus on like-for-like sales growth, volumes, regional performance, particularly in Europe and North America, and any commentary on full-year and medium-term guidance.
Further out, the full-year results in February 2027 could bring a reset of medium-term targets if JPMorgan's view proves correct.






Please wait processing your request...